Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049440 | 0.86 | MTNR1A (0.64) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL19151037 | 0.86 | LMNA (0.49) | MEN1KMT2A | |
| SCHEMBL18997723 | 0.82 | ALDH1A1 (0.51) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL14241869 | 0.80 | MTNR1A (0.72) | MTNR1AMTNR1B | |
| SCHEMBL26789763 | 0.77 | HTT (0.55) | MEN1KMT2A | |
| SCHEMBL23222222 | 0.75 | NOS3 (0.45) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL8871850 | 0.75 | MTNR1A (0.56) | MTNR1A | |
| SCHEMBL91395 | 0.75 | CA12 (0.50) | MEN1KMT2A | |
| SCHEMBL30421834 | 0.74 | POLB (0.51) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL20520330 | 0.74 | CA12 (0.44) | MEN1KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MEN1 4080/4885KMT2A 3544/4885MTNR1A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.